MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2006 » 2 » | Archive » Medical field » Research papers » Clinical research paper » Archive » Medical field » Fields » Oncology »

Frequency of BRCA1 and BRCA2 Gene Mutations in Slovenian Male Breast Cancer Patients

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Breast cancer is the most frequent cancer among women in Slovenia. Male breast cancer, how­ever, is a rare disease comprising less than 1% of breast cancer patients in Slovenia. The causes for some of inherited cases are mutations of the BRCA1 or BRCA2 genes. BRCA2 gene muta­tion carriers have an increased risk of breast cancer. It is estimated that 15% of men who carry a germ-line BRCA2 gene mutation will develop breast cancer. Studies in various countries have shown varying frequencies of BRCA2 gene mutations. There is no information about the frequency of mutation carriers in the Slovene male breast cancer population. The pur­pose of our population-based study was to determine the frequency of BRCA2 or BRCA1 gene mutation carriers among male breast cancer patients in Slovenia. Our study hypothesis was: The frequency of BRCA2 gene mutation carriers among male breast cancer cases is over 10%. Records on 136 male patients treated for breast cancer between 1975 and 2005 at the Ljubljana Institute of Oncology were retrieved. At the time of our study, 38 of those patients were still alive. They were invited to receive genetic counselling and undergo genetic testing. Genetic testing was performed using blood samples at the Laboratory of Oncological Genetics at the Vrije Universiteit in Brussels. The BRCA1 and BRCA2 genes were screened for mutations using the PTT and F-CSGE tests, then the high peaked samples were sequenced. Twenty-two male breast cancer patients were tested. BRCA2 gene mutation was identified in three male breast cancer patients. Two of them carried the Slovene founder mutation IVS16-2a > G. This muta­tion has been found in nine Slovene families so far. None of our patients had BRCA1 mutation. The median age of all our patients with breast cancer was 58 years (range 17 to 86 years). The median age of the patients with BRCA2 gene mutation was 64 years and of those with­out mutation it was 57 years. There was no statistical difference in the ages of the patients with mutation and those without it (p = 0.41). There was also no statistical difference in the stage of disease in patients with mutation and those without it (p = 0.21). The frequency of BRCA2 gene mutations among male breast cancer patients in Slovenia is 14%.

Authors:
Černivc Barbara, Bešić Nikola, Lokar Katarina, et al.

Keywords:
breasts neoplasms male − genetics, genes BRCA1, genes BRCA2, mutation

Cite as:
Med Razgl. 2006; 45: 129−39.

Download PDF >>
© 2022 Društvo Medicinski razgledi | Na vrh strani / To top ↑